<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35727129</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-4598</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Muscle &amp; nerve</Title><ISOAbbreviation>Muscle Nerve</ISOAbbreviation></Journal><ArticleTitle>Clinical and electrophysiological findings in C9ORF72 ALS.</ArticleTitle><Pagination><StartPage>270</StartPage><EndPage>275</EndPage><MedlinePgn>270-275</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mus.27665</ELocationID><Abstract><AbstractText Label="INTRODUCTION/AIMS">Amyotrophic lateral sclerosis (ALS) is a progressive, fatal, neurodegenerative disorder of motor neurons in which the cause is mostly unknown. Early identification of genetic ALS cases, of which C9ORF72 (C9ALS) is the most frequent, can have important implications for evaluation, prognosis, and therapeutics. Here, we aimed to characterize the clinical and electrophysiological hallmarks of C9ALS and investigate differences from C9ORF72 negative ALS (non-C9ALS).</AbstractText><AbstractText Label="METHODS">We retrospectively reviewed clinical and electrodiagnostic (EDX) data for all genetically confirmed C9ALS cases seen between 1/1/2012 and 10/1/2020 who met Gold Coast criteria and compared them 1:1 with non-C9ALS patients within the same time frame.</AbstractText><AbstractText Label="RESULTS">A total of 99 C9ALS and 99 non-C9ALS cases were identified. Compared to non-C9ALS, C9ALS demonstrated higher prevalence in women, lesser racial variability, stronger family history of ALS, and higher frequency of upper motor neuron signs. EDX testing of C9ALS showed higher median sensory nerve and lower fibular compound muscle action potential amplitudes.</AbstractText><AbstractText Label="DISCUSSION">Although the differences between C9ALS and non-C9ALS reached statistical significance in certain nerve conduction parameters, they were not sufficient to discriminate between groups on a case-by-case basis. Genetic testing is required to identify C9ALS patients.</AbstractText><CopyrightInformation>&#xa9; 2022 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sista</LastName><ForeName>Sri Raghav S</ForeName><Initials>SRS</Initials><Identifier Source="ORCID">0000-0002-5358-7373</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelly</LastName><ForeName>Shahar</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3585-1687</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Sheba Medical Center, Tel HaShomer, Sackler Faculty of Medicine, Tel Aviv University, Middle East, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskarsson</LastName><ForeName>Bj&#xf6;rn</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-1725-9866</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubin</LastName><ForeName>Devon I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Thompson</LastName><ForeName>Jennifer M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parra-Cantu</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staff</LastName><ForeName>Nathan P</ForeName><Initials>NP</Initials><Identifier Source="ORCID">0000-0001-6760-3859</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laughlin</LastName><ForeName>Ruple S</ForeName><Initials>RS</Initials><Identifier Source="ORCID">0000-0002-1884-5824</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Muscle Nerve</MedlineTA><NlmUniqueID>7803146</NlmUniqueID><ISSNLinking>0148-639X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Muscle Nerve. 2023 Mar;67(3):E7</RefSource><PMID Version="1">36566356</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">C9ORF72</Keyword><Keyword MajorTopicYN="N">electrodiagnostics</Keyword><Keyword MajorTopicYN="N">genetic testing</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>21</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35727129</ArticleId><ArticleId IdType="doi">10.1002/mus.27665</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Shepheard SR, Parker MD, Cooper-Knock J, et al. Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2021;92:510-518.</Citation></Reference><Reference><Citation>Roggenbuck J, Palettas M, Vicini L, Patel R, Quick A, Kolb SJ. Incidence of pathogenic, likely pathogenic, and uncertain ALS variants in a clinic cohort. Neurology. Genetics. 2020;6(1):e390.</Citation></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257-268.</Citation></Reference><Reference><Citation>DeJesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245-256.</Citation></Reference><Reference><Citation>Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617-628.</Citation></Reference><Reference><Citation>Majounie E, Renton AE, Mok K, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. The Lancet Neurology. 2012;11:323-330.</Citation></Reference><Reference><Citation>Umoh ME, Fournier C, Li Y, et al. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology. 2016;87:1024-1030.</Citation></Reference><Reference><Citation>Byrne S, Elamin M, Bede P, et al. Cognitive and clinical characteristics of patients with amyotrophic lateral sclerosis carrying a C9orf72 repeat expansion: a population-based cohort study. The Lancet Neurol. 2012;11:232-240.</Citation></Reference><Reference><Citation>Cooper-Knock J, Hewitt C, Highley JR, et al. Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain. 2012;135:751-764.</Citation></Reference><Reference><Citation>Irwin DJ, McMillan CT, Brettschneider J, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:163-169.</Citation></Reference><Reference><Citation>Miltenberger-Miltenyi G, Concei&#xe7;&#xe3;o VA, Gromicho M, et al. C9orf72 expansion is associated with accelerated decline of respiratory function and decreased survival in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2019;90:118-120.</Citation></Reference><Reference><Citation>Cammack AJ, Atassi N, Hyman T, et al. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019;93:e1605-e1617.</Citation></Reference><Reference><Citation>Zhu Q, Jiang J, Gendron TF, et al. Reduced C9ORF72 function exacerbates gain of toxicity from ALS/FTD-causing repeat expansion in C9orf72. Nat Neurosci. 2020;23:615-624.</Citation></Reference><Reference><Citation>Vajda A, McLaughlin RL, Heverin M, et al. Genetic testing in ALS: a survey of current practices. Neurology. 2017;88:991-999.</Citation></Reference><Reference><Citation>Pegat A, Bouhour F, Mouzat K, et al. Electrophysiological characterization of C9ORF72-associated amyotrophic lateral sclerosis: a retrospective study. Eur Neurol. 2019;82:106-112.</Citation></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131:1975-1978.</Citation></Reference><Reference><Citation>Interactive Product: Nerve Conduction Study Trainer. [online]. Accessed November 22, 2021.</Citation></Reference><Reference><Citation>Pugdahl K, Fuglsang-Frederiksen A, de Carvalho M, et al. Generalised sensory system abnormalities in amyotrophic lateral sclerosis: a European multicentre study. J Neurol Neurosurg Psychiatry. 2007;78:746-749.</Citation></Reference><Reference><Citation>Trojsi F, Siciliano M, Femiano C, et al. Comparative analysis of C9orf72 and sporadic disease in a large multicenter ALS population: the effect of male sex on survival of C9orf72 positive patients. Front Neurosci. 2019;13:485.</Citation></Reference><Reference><Citation>Sabatelli M, Conforti FL, Zollino M, et al. C9ORF72 hexanucleotide repeat expansions in the Italian sporadic ALS population. Neurobiol Aging. 2012;33:1848. e1815-1848. e1820.</Citation></Reference><Reference><Citation>Garc&#xed;a-Redondo A, Dols-Icardo O, Rojas-Garc&#xed;a R, et al. Analysis of the C 9orf72 gene in patients with amyotrophic lateral sclerosis in Spain and different populations worldwide. Hum Mutat. 2013;34:79-82.</Citation></Reference><Reference><Citation>Chi&#xf2; A, Borghero G, Restagno G, et al. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain. 2012;135:784-793.</Citation></Reference><Reference><Citation>Stewart H, Rutherford NJ, Briemberg H, et al. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol. 2012;123:409-417.</Citation></Reference><Reference><Citation>Shefner JM, Tyler HR, Krarup C. Abnormalities in the sensory action potential in patients with amyotrophic lateral sclerosis. Muscle &amp; Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 1991;14:1242-1246.</Citation></Reference><Reference><Citation>Mondelli M, Rossi A, Passero S, Guazzi GC. Involvement of peripheral sensory fibers in amyotrophic lateral sclerosis: electro-physiological study of 64 cases. Muscle &amp; Nerve: Official Journal of the American Association of Electrodiagnostic Medicine. 1993;16:166-172.</Citation></Reference><Reference><Citation>deCarvalho M, Gromicho M, Andersen P, et al. Peripheral neuropathy in ALS: phenotype association. J Neurol Neurosurg Psychiatry. 2021;92:1133-1134.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>